Published in Clin J Am Soc Nephrol on December 01, 2011
Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study. Arthritis Res Ther (2014) 0.98
Lymphopenia and treatment-related infectious complications in ANCA-associated vasculitis. Clin J Am Soc Nephrol (2012) 0.94
Is serum HMGB1 a biomarker in ANCA-associated vasculitis? Arthritis Res Ther (2013) 0.88
Glomerular disease in patients with infectious processes developing antineutrophil cytoplasmic antibodies. ISRN Nephrol (2013) 0.87
Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis. J Am Soc Nephrol (2017) 0.86
Glomerular disease: ANCA-associated GN--to PLEX or not to PLEX? Nat Rev Nephrol (2013) 0.83
Current and future prospects in the management of granulomatosis with polyangiitis (Wegener's granulomatosis). Ther Clin Risk Manag (2014) 0.82
Current therapy of granulomatosis with polyangiitis and microscopic polyangiitis: the role of rituximab. J Nephrol (2014) 0.80
Adverse events and infectious burden, microbes and temporal outline from immunosuppressive therapy in antineutrophil cytoplasmic antibody-associated vasculitis with native renal function. Nephrol Dial Transplant (2015) 0.79
Long-term outcome of mycophenolate mofetil treatment for patients with microscopic polyangiitis: an observational study in Chinese patients. Rheumatol Int (2016) 0.78
Maintenance of clinical remission in ANCA-associated vasculitis. Nat Rev Rheumatol (2012) 0.78
Granulomatosis with polyangiitis (Wegener's) as a necrotizing gingivitis mimic: a case report. J Med Case Rep (2014) 0.75
Benefits of an expanded use of plasma exchange for anti-neutrophil cytoplasmic antibody-associated vasculitis within a dedicated clinical service. BMC Musculoskelet Disord (2015) 0.75
Trends in Long-Term Outcomes Among Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis With Renal Disease. Arthritis Rheumatol (2016) 0.75
Different responses to treatment across classified diseases and severities in Japanese patients with microscopic polyangiitis and granulomatosis with polyangiitis: a nationwide prospective inception cohort study. Arthritis Res Ther (2015) 0.75
What Everybody is Doing but No One is Talking About: Use of Complementary and Alternative Medicine in the ANCA Associated Vasculitis Population. J Autoimmune Dis Rheumatol (2014) 0.75
Updates in ANCA-associated vasculitis. Eur J Rheumatol (2016) 0.75
Spotlight on rituximab in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis: current perspectives. Ther Clin Risk Manag (2015) 0.75
Pituitary granulomatosis with polyangiitis. BMJ Case Rep (2013) 0.75
Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum (1994) 14.16
A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med (2003) 7.30
Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med (2005) 3.18
Cyclophosphamide therapy in Wegener's granulomatosis. N Engl J Med (1971) 2.33
Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum (2008) 2.26
Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol (1996) 2.08
Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol (1996) 1.95
Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology (Oxford) (2007) 1.95
Effect of cyclophosphamide upon the immune response in Wegener's granulomatosis. N Engl J Med (1971) 1.70
Improved outcome in 445 patients with Wegener's granulomatosis in a German vasculitis center over four decades. Arthritis Rheum (2011) 1.60
Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. Arthritis Rheum (2003) 1.52
Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis. Arthritis Care Res (Hoboken) (2010) 1.45
ANCA disease: where is this field heading? J Am Soc Nephrol (2010) 1.33
High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate. Arthritis Rheum (2002) 1.07
Adverse effects of therapy for ANCA-associated vasculitis. Best Pract Res Clin Rheumatol (2009) 1.07
Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med (2003) 1.03
Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest (2002) 5.42
Focal segmental glomerulosclerosis. N Engl J Med (2011) 3.77
Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med (2005) 3.18
Autoimmunity is triggered by cPR-3(105-201), a protein complementary to human autoantigen proteinase-3. Nat Med (2003) 2.85
Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int (2011) 2.43
Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol (2007) 2.41
Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum (2008) 2.26
Discrepancy between Medical Evidence Form 2728 and renal biopsy for glomerular diseases. Clin J Am Soc Nephrol (2010) 2.25
Venous thromboembolism in patients with membranous nephropathy. Clin J Am Soc Nephrol (2011) 2.18
Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum (2012) 2.17
Pathogenesis of antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis. Annu Rev Pathol (2013) 2.02
Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis. J Clin Invest (2013) 1.99
The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies. Am J Pathol (2005) 1.97
Association between thyroid disease and its treatment with ANCA small-vessel vasculitis: a case-control study. Nephrol Dial Transplant (2007) 1.89
Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin J Am Soc Nephrol (2010) 1.89
Epigenetic basis for aberrant upregulation of autoantigen genes in humans with ANCA vasculitis. J Clin Invest (2010) 1.87
Anti-LAMP-2 antibodies are not prevalent in patients with antineutrophil cytoplasmic autoantibody glomerulonephritis. J Am Soc Nephrol (2011) 1.82
Periodontal disease adversely affects the survival of patients with end-stage renal disease. Kidney Int (2009) 1.74
Patients with antineutrophil cytoplasmic antibody-associated vasculitis have defective Treg cell function exacerbated by the presence of a suppression-resistant effector cell population. Arthritis Rheum (2013) 1.70
Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. Kidney Int (2013) 1.69
Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-alpha. Am J Pathol (2005) 1.65
Rituximab therapy for membranous nephropathy: a systematic review. Clin J Am Soc Nephrol (2009) 1.62
SCreening for Occult REnal Disease (SCORED): a simple prediction model for chronic kidney disease. Arch Intern Med (2007) 1.56
The clinical course of ANCA small-vessel vasculitis on chronic dialysis. Kidney Int (2009) 1.54
Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis (2003) 1.53
DRB1*15 allele is a risk factor for PR3-ANCA disease in African Americans. J Am Soc Nephrol (2011) 1.51
Cutaneous and systemic manifestations of drug-induced vasculitis. Ann Pharmacother (2002) 1.48
Pathogenesis of vascular inflammation by anti-neutrophil cytoplasmic antibodies. J Am Soc Nephrol (2006) 1.48
The effect of cholesterol reduction with cholestyramine on renal function. Am J Kidney Dis (2005) 1.46
Association of silica exposure with anti-neutrophil cytoplasmic autoantibody small-vessel vasculitis: a population-based, case-control study. Clin J Am Soc Nephrol (2007) 1.46
C5a receptor (CD88) blockade protects against MPO-ANCA GN. J Am Soc Nephrol (2013) 1.38
Clinical trials treating focal segmental glomerulosclerosis should measure patient quality of life. Kidney Int (2010) 1.38
Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. Ann Rheum Dis (2011) 1.33
Periodontal disease is associated with renal insufficiency in the Atherosclerosis Risk In Communities (ARIC) study. Am J Kidney Dis (2005) 1.31
High prevalence of sickle cell trait in African Americans with ESRD. J Am Soc Nephrol (2010) 1.23
Bone marrow-derived cells are sufficient and necessary targets to mediate glomerulonephritis and vasculitis induced by anti-myeloperoxidase antibodies. J Am Soc Nephrol (2006) 1.20
The effect of conflicting medication information and physician support on medication adherence for chronically ill patients. Patient Educ Couns (2009) 1.18
Molecular cloning, genomic structure, and expression analysis of MUC20, a novel mucin protein, up-regulated in injured kidney. J Biol Chem (2003) 1.17
Management patterns of childhood-onset nephrotic syndrome. Pediatr Nephrol (2009) 1.16
ANCA are pathogenic--oh yes they are! J Am Soc Nephrol (2002) 1.15
Circumvention of normal constraints on granule protein gene expression in peripheral blood neutrophils and monocytes of patients with antineutrophil cytoplasmic autoantibody-associated glomerulonephritis. J Am Soc Nephrol (2004) 1.14
Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis. Kidney Int (2011) 1.13
Decreased CD5⁺ B cells in active ANCA vasculitis and relapse after rituximab. Clin J Am Soc Nephrol (2013) 1.12
A clinical tool to measure the components of health-care transition from pediatric care to adult care: the UNC TR(x)ANSITION scale. Ren Fail (2012) 1.09
Predictors of relapse and end stage kidney disease in proliferative lupus nephritis: focus on children, adolescents, and young adults. Clin J Am Soc Nephrol (2009) 1.09
Long-term glycemic control measurements in diabetic patients receiving hemodialysis. Am J Kidney Dis (2002) 1.08
A novel subset of memory B cells is enriched in autoreactivity and correlates with adverse outcomes in SLE. Clin Immunol (2008) 1.08
Positive association of renal insufficiency with agriculture employment and unregulated alcohol consumption in Nicaragua. Ren Fail (2010) 1.07
Pathogenesis of antineutrophil cytoplasmic autoantibody vasculitis. Curr Opin Nephrol Hypertens (2011) 1.06
Health-related quality of life for patients with vasculitis and their spouses. Arthritis Rheum (2009) 1.06
NPHS2 variation in focal and segmental glomerulosclerosis. BMC Nephrol (2008) 1.04
A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. Nephrol Dial Transplant (2005) 1.02
ANCA patients have T cells responsive to complementary PR-3 antigen. Kidney Int (2008) 1.02
Nosology of primary vasculitis. Curr Opin Rheumatol (2007) 1.01